ALS and Medical Cannabis in Texas: Eligibility, Evidence, and Safety

Texas gives people with ALS a legal pathway to a low-THC cannabis prescription, but the medical decision is more specific than the diagnosis alone. A useful evaluation identifies the symptom being targeted, considers breathing and swallowing changes, and protects the treatments and support that already form the center of ALS care.

ALS Qualifies Under the Texas Compassionate Use Program

The Texas Department of Public Safety lists amyotrophic lateral sclerosis as a qualifying condition for permanent Texas residents.¹ The enacted statute also names ALS directly and requires the prescribing physician to decide that the potential benefit is reasonable in light of the risk.²

That legal status answers an eligibility question. It does not mean every person with ALS will receive a prescription, that every ALS symptom will respond, or that the state has endorsed cannabis as a treatment for the underlying disease. Approval is not guaranteed.

What the Clinical Evidence Actually Shows

The most relevant controlled human study is the CANALS phase 2 trial. It enrolled 60 people with ALS or primary lateral sclerosis who had spasticity and compared an oromucosal THC-CBD spray with placebo for six weeks. Among the 59 participants included in the analysis, the treatment group had a modest improvement on the Modified Ashworth Scale relative to placebo. The trial reported no serious adverse events and no withdrawals during the double-blind phase.³

This was a short proof-of-concept study of one standardized prescription spray in a selected group. It does not establish that cannabis slows motor-neuron loss, preserves breathing, extends survival, or produces the same result with retail gummies, oils, flower, or other formulations.

A 2025 review of cannabinoids and ALS reached a similarly cautious conclusion. Laboratory findings continue to generate interest, but human research remains limited, and larger well-designed trials are needed before any disease-modifying claim can be supported.⁴

Keep the ALS Care Plan at the Center

Current motor-neuron disease guidance emphasizes coordinated multidisciplinary care and established symptom treatments. For spasticity, for example, the NICE guideline discusses medicines such as baclofen, tizanidine, dantrolene, and gabapentin, with specialist input when symptoms are severe.⁵ A cannabinoid discussion belongs inside that broader plan, not beside it.

A practical evaluation should begin with one measurable goal. “Improve nighttime spasms without worse morning weakness” is more useful than “see if cannabis helps.” The patient and care team can then agree on a time frame, a starting plan, warning signs, and a stopping rule if the intended benefit does not appear.

• Name the exact symptom and record its baseline frequency or severity.
• Review current medicines, supplements, alcohol use, and prior reactions to THC or CBD.
• Decide who will monitor changes in alertness, balance, transfers, speech, appetite, and sleep.
• Protect physical therapy, communication, respiratory, nutrition, and mobility goals.
• Plan how to distinguish a side effect from a change in ALS that needs prompt clinical attention.

Breathing and Swallowing Change the Risk Conversation

ALS may weaken the muscles used for breathing, coughing, and swallowing. The ALS Association notes that an ineffective cough can make it harder to clear the airway, while swallowing problems can allow food or liquid to enter the lungs.⁶ Those changes can affect whether an oral product is practical and how concerning sedation or dizziness may be.

The FDA has also identified additive central nervous system effects from delta-9 THC, including dizziness, confusion, sedation, and sleepiness.⁸ For a person already managing weakness, falls, fatigue, or assisted transfers, even a modest increase in sedation can matter.

Texas law excludes smoking from medical use. It allows pulmonary inhalation only when a physician determines that route is medically necessary and specifies the dose, using devices approved under state rules.² Legal availability does not make an inhaled route appropriate for a person with respiratory weakness. That question belongs with the prescribing physician and ALS respiratory team.

Questions to Take to the Neurologist and Registered Physician

• Which symptom are we treating, and what outcome would count as a meaningful benefit?
• Could THC or CBD interact with riluzole, edaravone, spasticity medicines, sleep medicines, opioids, anxiety medicines, or supplements?
• Do swallowing, coughing, breathing, or feeding-tube changes affect the product form?
• Could sedation or dizziness increase fall, transfer, wheelchair, or communication risk?
• Who should be contacted if weakness, confusion, shortness of breath, or swallowing worsens?
• When will the plan be reassessed, and when should the product be stopped?

How the Texas Prescription Process Works

A permanent Texas resident can use the official CURT physician search to find participating clinicians.⁷ The physician confirms the qualifying diagnosis, weighs expected benefit against risk, and decides whether to prescribe. Patients do not self-register in CURT and do not pay a state registration fee.

If approved, the registered physician enters the prescription in CURT. The patient or legal guardian can then work with a licensed Texas dispensing organization, which verifies the prescription in the registry. Our Texas qualifying conditions guide explains the broader eligibility list, and the medical cannabis hub collects practical access and patient guides.